# Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

- Link: https://www.thailand-business-news.com/pr-news/brii-biosciences-provides-corporate-updates-and-reports-2026-interim-financial-results
- Published: 2026-08-21T06:10:00+07:00
- Author: PR Newswire

_Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional
Data Expected in 2H 2026_

_Emerging Discovery Programs Build Momentum_

_BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC_

_Strong Cash Position Supports Continued Strategic Execution_

_Conference Call Scheduled: August 21 at 8:30 a.m. HKT _

DURHAM, N.C. and BEIJING, Aug. 21, 2026 /PRNewswire/ — [Brii Biosciences Limited](https://www.briibio.com/en/)("
Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing
therapies to improve patient health and choice across diseases with high unmet medical
need, today provided a corporate update and reported its financial results for the
six-month period ended June 30, 2026.

In the first half of 2026, Brii Bio generated additional clinical data supporting
its differentiated hepatitis B virus (HBV) functional cure strategy while continuing
to expand its internal discovery capabilities and advance its RNA-based technology
platforms.

In its HBV clinical program, the Company presented end-of-study data from its Phase
2 ENSURE study at the European Association for the Study of the Liver (EASL) Congress
2026. On July 3, the Company also announced topline end-of-treatment data from its
Phase 2b ENRICH and ENHANCE studies. To date, findings across the ENSURE, ENRICH
and ENHANCE studies have consistently supported the potential of BRII-179 to improve
functional cure outcomes as part of a combination regimen. Detailed data from the
ENRICH and ENHANCE studies are expected to be presented in the second half of 2026.

Beyond its HBV portfolio, the Company continued to advance its internal discovery
capabilities and invest in the development of RNA-based technology platforms. Subsequent
to the reporting period, the first participant was dosed in a clinical study evaluating
BRII-5395, an internally discovered mRNA therapeutic vaccine for advanced hepatocellular
carcinoma (HCC). This milestone represents the first clinical evaluation of an RNA-
based therapeutic originating from Brii Bio’s internal discovery efforts. While 
BRII-5395 is an mRNA therapeutic vaccine, the Company’s broader RNA platforms encompass
multiple RNA modalities. During the first half of 2026, Brii Bio progressed multiple
internally discovered candidates across various stages of discovery and preclinical
development, including programs that extend the application of its technology platforms
into additional therapeutic areas beyond infectious diseases.

With effective cost control measures and optimized operating structure in place,
Brii Bio remains well-capitalized, with a cash position of approximately US$260 
million as of June 30, 2026, providing financial flexibility to support its late-
stage HBV programs and early discovery initiatives.

"Our progress in the first half of the year reflects meaningful advances across 
both our late-stage HBV portfolio and our expanding discovery capabilities," said
Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio. "Data generated 
across our HBV studies continue to inform our functional cure strategy. At the same
time, the initiation of clinical evaluation for BRII-5395 demonstrates our ability
to translate internal discovery into pipeline assets. We look forward to sharing
additional milestones later this year. Together, these efforts are building a more
diversified pipeline and strengthening the foundation for sustainable innovation
and long-term value creation."

**Corporate and Clinical Updates**

**HBV Program**

Brii Bio continued to advance its HBV pipeline with a focus on achieving higher 
functional cure rates through novel combination regimens. The Company’s differentiated
HBV portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic,
and elebsiran, an HBV-targeting siRNA, has generated a growing body of clinical 
data supporting Brii Bio’s functional cure strategy through the completed Phase 
2b ENSURE study and ongoing ENRICH and ENHANCE Phase 2b studies.

 ◦ The Phase 2b ENSURE study was designed to assess the safety and efficacy of combination
   approaches aimed at improving functional cure outcomes. Cohorts 1-3 evaluated
   elebsiran in combination with PEG-IFNα compared to PEG-IFNα monotherapy. Cohort
   4 evaluated the potential role of BRII-179 in enhancing immune responsiveness
   and improving hepatitis B surface antigen (HBsAg) loss rates. In the first half
   of 2026, end-of-study data from Cohorts 1-4 of the Phase 2 ENSURE study were 
   presented at EASL 2026, demonstrating that:
    ◦ The HBsAg loss benefit observed in the elebsiran and PEG-IFNα combination 
      cohorts resulted in a higher functional cure rate compared to the PEG-IFNα
      alone cohort.
    ◦ BRII-179-experienced participants achieved higher functional cure rates, particularly
      among anti-HBs responders, suggesting that BRII-179 may play an important 
      role in achieving durable immunological control of HBV. 
 ◦ To further define the role of BRII-179 in HBV treatment and identify an optimal
   combination regimen for potential registrational development, the Company is 
   evaluating BRII-179 in two additional ongoing Phase 2b studies: ENRICH and ENHANCE
   studies.
 ◦ The ENRICH study evaluates BRII-179 as a priming therapy administered prior to
   elebsiran and PEG-IFNα treatment. The ENHANCE study evaluates a concurrent triple
   combination regimen of BRII-179, elebsiran, and PEG-IFNα to enhance the functional
   cure rates. In July, the Company announced topline end-of-treatment data from
   its Phase 2b ENRICH and ENHANCE studies.
    ◦ At EOT, the ENRICH study evaluating pre-treatment with BRII-179 followed by
      elebsiran and PEG-IFNα achieved HBsAg loss rates of 42.9% (42/98) and 40.0%(
      20/50) across two BRII-179 dosing schedules (five doses administered every
      3 weeks and 7 doses administered every 2 weeks, respectively). These results
      were consistent with the 41.9% (13/31) HBsAg loss rate observed in ENSURE 
      Cohort 4 among patients previously treated with BRII-179, supporting the potential
      immune-priming role of BRII-179.
    ◦ Subgroup analyses from the ENRICH study suggest potential differentiation 
      in subjects with higher baseline HBsAg levels (1000-3000 IU/mL) comparing 
      with other HBV functional cure regimens under development by other companies,
      consistent with prior findings from ENSURE Cohort 4, indicating that BRII-
      179 may induce beneficial immune responses regardless of baseline HBsAg levels
      in this difficult-to-treat population.
    ◦ At EOT, the ENHANCE (Part A-1) study evaluating a concurrent triple combination
      did not demonstrate improved HBsAg loss rates compared with ENSURE Cohorts
      2 and 3, 29.7% (11/37), with an observed rate of 25.5% (25/98). Higher HBsAg
      loss rates, however, were observed compared with the PEG-IFNα control arm,
      10.2% (5/49).
    ◦ The ENHANCE study also evaluated a sequential approach designed to potentially
      shorten PEG-IFNα therapy in its Part A-2 by administering BRII-179 plus elebsiran
      during the first 24 weeks followed by 24 weeks of elebsiran and PEG-IFNα. 
      At EOT, this combination regimen achieved an HBsAg loss rate of 22.5% (18/
      80), suggesting that a full course of PEG-IFNα therapy may be important for
      achieving optimal functional cure outcomes.

No new safety concerns have been identified across ENSURE, ENRICH and ENHANCE to
date.

On August 19, 2026, the Company received an email notification from one of its central
laboratory service providers of a product recall involving a commercial assay kit
^([1]) used for HBsAg testing in the ENHANCE study. Based on the information currently
available and the Company’s preliminary assessment, the potential impact on the 
clinical data of the Company’s sponsored trials publicly disclosed to date appears
limited to the EOT HBsAg data for Part A-2 of the ENHANCE study. The Company is 
working with the service provider to identify potentially affected samples and arrange
retesting using unaffected assay kits. Subject to completion of the retesting and
further analysis, as at the date of this announcement, the Company has not identified
any indication at this stage that the matter would materially affect its overall
interpretation of the study results or the program development decisions announced
to date. The Company will continue to evaluate the matter and provide updates as
appropriate if any material developments arise.

The Company plans to present detailed data from the ENRICH and ENHANCE studies, 
including additional efficacy, safety and subgroup analyses, at a scientific conference
in the second half of 2026.

**Discovery Program Update**

Brii Bio is expanding its RNA platforms beyond infectious diseases into new therapeutic
areas. In the first half of 2026, the Company progressed multiple early-stage candidates
spanning various stages of discovery and pre-clinical development, with a focus 
on generating differentiated therapeutic opportunities in diseases with significant
unmet medical needs.

 ◦ BRII-5395 is a novel mRNA therapeutic vaccine internally developed by Brii Bio.
   It is being evaluated as part of a combination immunotherapy approach for HBV-
   related HCC.
    ◦ On August 12, 2026, subsequent to the reporting period, the first participant
      was dosed in a clinical study evaluating BRII-5395 in participants with advanced
      HCC. The study, conducted at the Cancer Hospital of the Chinese Academy of
      Medical Sciences, is designed to evaluate the safety, tolerability, immunogenicity
      and preliminary anti-tumor activity of BRII-5395 in combination with an anti-
      PD-1 antibody and an anti-VEGF antibody. The current standard of care of immune
      checkpoint inhibitors have limited efficacy against HCC.
    ◦ As the first internally developed mRNA-based cancer therapeutic vaccine from
      Brii Bio to enter clinical evaluation, BRII-5395 represents an important milestone
      in the advancement of the Company’s internal discovery capabilities and RNA-
      based technology platform.

While BRII-5395 is an mRNA therapeutic vaccine, the Company’s broader RNA platforms
encompass multiple RNA modalities. In addition, the Company has extended the application
of its technology platforms into additional therapeutic areas beyond infectious 
diseases.

Further program updates are expected throughout the remainder of 2026. The Company
is actively exploring partnership opportunities to advance selected discovery programs
to maximize the value of its emerging pipeline.

**Additional Clinical Programs**

 ◦ Brii Bio is actively seeking strategic partnerships for long-acting anti-HIV 
   and multidrug resistant (MDR) antibacterial therapeutic candidates to maximize
   the development and commercialization potential.

**Other Corporate Updates**

On April 16, 2026, the Company and Brii Biosciences Offshore Limited, a subsidiary
of the Company, submitted a Demand for Arbitration to the United States-based Judicial
Arbitration and Mediation Services, Inc. against Vir Biotechnology, Inc. (the "Arbitration").

The Company announced the commencement of the Arbitration on April 16, 2026 and 
provided a further update on May 22, 2026. As of June 30, 2026, the Arbitration 
remained in its early stages, and the parties had not reached a resolution of the
claims.

In light of the ongoing arbitration, the Company is not currently advancing elebsiran
into Phase 3 development and future development plans for elebsiran remain under
evaluation pending resolution of the Arbitration. The Company will continue to monitor
developments and update shareholders as appropriate.

**Outlook**

Looking ahead, the Company remains focused on advancing its differentiated HBV portfolio
while continuing to progress its RNA-based discovery efforts.

The Company plans to continue investing in its internal discovery capabilities and
RNA platform to support the advancement of future pipeline candidates. Through these
efforts, Brii Bio aims to generate new therapeutic opportunities and build a sustainable
pipeline of innovative medicines addressing diseases with significant unmet medical
needs.

With a strong balance sheet and disciplined execution, Brii Bio is well positioned
to pursue value-creating opportunities and deliver on its strategic priorities.

**Interim 2026 Financial Results**

 ◦ The Company maintains a strong cash position to support its operations through
   2029. Our bank deposits and cash and cash equivalents were RMB1,770.8 million
   as of June 30, 2026, representing a decrease of RMB170.2 million or 8.8% compared
   with RMB1,941.0 million as of December 31, 2025. The decrease was primarily due
   to payout of research and development activities and daily operations.
 ◦ Through pipeline prioritization, resource optimization, internalization of certain
   clinical development activities, and cost-saving measures of third-party vendors,
   we have effectively controlled our operational expenses. Research and development
   expenses were RMB98.3 million for the six months ended June 30, 2026, representing
   a decrease of RMB18.7 million or 16.0%, compared with RMB117.0 million for the
   six months ended June 30, 2025. The decrease was primarily attributable to organizational
   optimization, compensation framework adjustments, and lower third-party contracting
   costs as Phase 2 study activities for the HBV programs wound down, partially 
   offset by increased investment in early-stage discovery.
 ◦ Administrative expenses were RMB52.6 million for the six months ended June 30,
   2026, representing a decrease of RMB5.6 million or 9.6%, compared with RMB58.2
   million for the six months ended June 30, 2025. The decrease primarily reflected
   lower employee costs following organizational optimization and adjustments to
   the senior management compensation framework, partially offset by the increase
   in professional fees and the depreciation and amortization cost.
 ◦ Other income was RMB19.5 million for the six months ended June 30, 2026, representing
   a decrease of RMB8.6 million or 30.6%, compared with RMB28.1 million for the 
   six months ended June 30, 2025. This was mainly due to the decrease in bank interest
   income of RMB7.9 million attributable to the declining interest rates on time
   deposits.

**Conference Call Information**

The Company will host a live conference call in Chinese on August 21 at 8:30 a.m.
HKT (8:30 p.m. ET on August 20). For the registration link, please click [here](https://s.comein.cn/apcvu5rz).

All participants shall use the link provided above to complete the online registration
process prior to the conference call. A replay of the conference call will be available
after the call and can be accessed by visiting the Company’s website at [www.briibio.com](https://www.briibio.com/en/)
under the Investor Relations section.

This press release contains references to third-party information. Such information
is not deemed to be incorporated by reference in this press release. Brii Bio disclaims
responsibility for such third-party information.

**About Brii Bio**

Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company
developing therapies to improve patients’ health by addressing high unmet medical
needs with limited treatment options. The Company is advancing a broad pipeline 
of unique therapeutic candidates with lead programs against hepatitis B virus (HBV)
infection. The Company is led by a visionary and experienced leadership team and
has operations in both China and the United States. For more information, visit 
[www.briibio.com](http://www.briibio.com/).

**Forward-Looking Statement**

The information communicated in this press release contains certain statements that
are or may be forward-looking. These statements typically contain words such as "
will," "expects," "believes," "plans" and "anticipates," and words of similar import.
By their nature, forward-looking statements involve risk and uncertainty because
they relate to events and depend on circumstances that will occur in the future.
There may be additional material risks that are currently not considered to be material
or of which the Company is unaware. These forward-looking statements are not a guarantee
of future performance. Against the background of these uncertainties, readers should
not rely on these forward-looking statements. The Company assumes no responsibility
to update forward-looking statements or to adapt them to future events or developments.

  |

^([1]) The relevant kit is Roche Elecsys HBsAg II quant II. For details of the product recall, please see the public recall announcement: [https://qxzh.yjj.sh.gov.cn/openApi/recallDetail?recall.recallId=525e2adbd3454202bdc748ad47efb17a](https://qxzh.yjj.sh.gov.cn/openApi/recallDetail?recall.recallId=525e2adbd3454202bdc748ad47efb17a) 

  |

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results ](http://www.prnasia.com/story/archive/5030554_AE30554_0?rand=184833)
